Skip to content

GE HealthCare Technologies

US · GEHC #689 by market cap Listed 2022
80.64 -1.25 -1.53%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Mixed / stable
  • The number of reporting institutions decreased by 1 in the most recent period (2026/Q4).
  • Total institutional ownership (as a % of shares) was little changed.

Institutional ownership

Held by institutions
94.86%
Institutions
1,488 -1
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund82.34%
Public Company3.43%
Hedge Fund3.16%
Government Pension Fund1.88%
Private Company1.43%
Sovereign Wealth Fund1.33%
VC/PE Fund0.43%
Family Office/Trust0.30%
Insurance Company0.23%
Individual/Insider0.22%
Other5.48%

Top holders as of 2026-09-30

Dodge & Cox 10.68% · 48.30M sh
BlackRock 8.26% · 37.34M sh
Vanguard Capital Management, LLC 7.11% · 32.14M sh
State Street Global Advisors 4.64% · 21.00M sh
Vanguard Portfolio Management, LLC 4.41% · 19.94M sh
Invesco Capital Management LLC 3.42% · 15.46M sh
Harris Associates L.P. 3.29% · 14.87M sh
Barrow, Hanley, Mewhinney & Strauss, LLC 3.05% · 13.77M sh
Hotchkis and Wiley Capital Management, LLC 2.95% · 13.34M sh
Geode Capital Management, LLC 2.86% · 12.94M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 30 buys · 17 sells

NameRoleStake
H. Culp Independent Chairperson 0.11%
Peter Arduini Chief Executive Officer 0.03%
Frank Jimenez General Counsel 0.02%
Taha Kass-Hout Chief Science & Technology Officer 0.01%
James Saccaro Former Vice President 0.01%
Kevin O’Neill President & CEO of Pharmaceutical Diagnostics 0.00%
Kenneth Stacherski Former Chief Global Supply Chain & Service Officer 0.00%
Anne Madden Independent Director 0.00%
Roland Rott Former President & CEO of Imaging 0.00%
Catherine Estrampes Chief Commercial & Growth Officer and Head of Global Markets 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-03 James Saccaro Former Vice President Intent to Sell (Form 144) -78,348 $85.92
2026-09-13 William Grogan Chief Financial Officer Other Acquisition +75,096 --
2026-09-13 William Grogan Chief Financial Officer Other Derivative Acquisition +31,877 $64.25
2026-09-02 Peter Arduini Chief Executive Officer Sale to Issuer -6,303 $70.56
2026-09-02 George Newcomb Controller & Chief Accounting Officer Sale to Issuer -112 $70.56
2026-09-02 Frank Jimenez General Counsel Sale to Issuer -1,480 $70.56
2026-09-02 Adam Holton Chief Human Resources Officer Sale to Issuer -673 $70.56
2026-09-02 Catherine Estrampes Chief Commercial & Growth Officer and Head of Global Markets Sale to Issuer -508 $70.56
2026-09-02 Philip Rackliffe President & CEO of Advanced Imaging Solutions (AIS) Sale to Issuer -798 $70.56
2026-09-02 Kevin O’Neill President & CEO of Pharmaceutical Diagnostics Sale to Issuer -718 $70.56
2026-09-02 Taha Kass-Hout Chief Science & Technology Officer Sale to Issuer -1,502 $70.56
2026-08-31 Peter Arduini Chief Executive Officer Sale to Issuer -11,515 $71.23
2026-08-31 Frank Jimenez General Counsel Sale to Issuer -3,131 $71.23
2026-08-31 Adam Holton Chief Human Resources Officer Sale to Issuer -659 $71.23
2026-08-31 Jeannette Bankes President & CEO of Patient Care Solutions Sale to Issuer -1,064 $71.23
2026-08-31 Philip Rackliffe President & CEO of Advanced Imaging Solutions (AIS) Sale to Issuer -856 $71.23
2026-08-31 Taha Kass-Hout Chief Science & Technology Officer Sale to Issuer -2,940 $71.23
2026-08-14 Adam Holton Chief Human Resources Officer Sale to Issuer -1,360 $73.69
2026-05-21 Kevin Lobo Independent Director Open Market Acquisition +10,000 $64.18
2026-05-14 Jeannette Bankes President & CEO of Patient Care Solutions Sale to Issuer -5,535 $62.67

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

GE HealthCare Technologies discussion 0 comments

Add a comment